Skip to main content

Introduction

This analysis contains data on incidence, mortality, stage and survival of patients with ovary, fallopian tube and primary peritoneal carcinomas in England. These data support the report "Ovary, fallopian tube and primary peritoneal carcinoma: Incidence, mortality, stage and survival" as part of the Ovarian Cancer Audit Feasibility Pilot, available on the NCRAS website.

The Ovarian Cancer Audit Feasibility Pilot is a collaboration between the gynaecological oncology clinical community, the charity sector and Public Health England to perform meaningful analysis of routinely collected data for the purposes of improving care and outcomes for women diagnosed with ovarian cancer in England. The Ovarian Cancer Audit Feasibility Pilot is jointly funded by The British Gynaecological Cancer Society, Target Ovarian Cancer and Ovarian Cancer Action and is being delivered by analysts at the National Cancer Registration and Analysis Service, part of Public Health England. The pilot will run for 2 years and will publish a range of data outputs on ovarian cancer throughout that time, including a final report on the audit and its findings, bringing all the analysis into one place.

The workbook constitutes the first in a series of analyses for the 2 year project. It provides a detailed insight into the status of this disease in England at the commencement of the project, including details of disease incidence, mortality and survival. In keeping with international ovarian cancer analyses, we have included cases of ovary, fallopian tube and primary peritoneal cancer within our definition of “ovarian cancer” in these analyses, and for the survival statistics we have excluded ovarian tumours of borderline malignant potential (except where specifically indicated for historical comparison purposes).

Full details of the Ovarian Cancer Audit Feasibility Pilot can be found on the project page on this website.

You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. 

To view this licence, visit https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/ or email [email protected].

Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

When you use this information under the Open Government Licence, you should include the following attribution: “Data for this study/ project/ report* is based on patient-level information collected by the NHS, as part of the care and support of cancer patients. The data is collated, maintained and quality assured by the National Cancer Registration and Analysis Service, which is part of Public Health England (PHE).”
* Delete as appropriate or adapt to reflect output type


Content overview

The data workbook contains the following tables:

Tables

Cohort definition (ICD-10/ICD-O-2)

Source

Time period

Ages

Output types

Tables

Table 1 - Incidence

C56, C57, C48 excluding sarcomas [note 1], D39.1

CAS1906 and ONS2017

2015 to 2017 (combined)

all ages

counts, crude and age-standardised rates

Table 1 - Incidence

Table 2 - Incidence time series

C56, C57, C48 excluding sarcomas [note 1], D39.1

CAS1907 and ONS2017

2001 to 2017 (annual time series)

all ages

counts, crude rates

Table 2 - Incidence time series

Table 3 - Mortality

C56-C57

CancerStats 2

2015 to 2017 (combined)

all ages

counts, crude and age-standardised rates

Table 3 - Mortality

Table 4 - Stage

C56, C57, C48 excluding sarcomas [note 1], D39.1

CAS1906 (with stage_best)

2015 to 2017 (combined)

all ages

counts, proportions

Table 4 - Stage

Notes:

  1. Sarcoma exclusions for C48: ICD-O-2 morphologies 8693, 8800, 8801, 8802, 8803, 8804, 8805, 8806, 8963, 8990, 8991, 9040, 9041, 9042, 9043, 9044, 8810, 8811 – 8921, 9120 – 9373, 9490, 9500, 9530 – 9582.
  2. Borderline exclusions for C56, C57, C48: ICD-O-2 morphologies 8442, 8444, 8451, 8463, 8473, 8472, 8462.
  3. Additional cohort restrictions apply to survival estimates (e.g. no DCOs), following Survival SOP v11
  4. Survival estimates have been age-standardised with ICSS weights where possible.
  5. Further details available in the Appendices to the main report, "Disease Profile in England: Incidence, mortality, stage and survival for ovary, fallopian tube and primary peritoneal carcinomas"

Download

Please select the box below to download the data tables:

(All content in the workbook is available under the Open Government Licence (OGL) v3.0, except where otherwise stated.)

Last edited: 16 January 2023 1:57 pm